Clinical Trial Update: Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating sorafenib in combination with capecitabine and cisplatin (XP) for advanced gastric cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Asan Medical Center | Conditions: Advanced Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-08-31